Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease

@inproceedings{Lannfelt2014PerspectivesOF,
  title={Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease},
  author={Lars Lannfelt and Christer M{\"o}ller and Hans Basun and Gunilla Osswald and Dag Sehlin and Andrew Satlin and Veronika Logovinsky and P{\"a}r Gellerfors},
  booktitle={Alzheimer's Research & Therapy},
  year={2014}
}
The symptomatic drugs currently on the market for Alzheimer’s disease (AD) have no effect on disease progression, and this creates a large unmet medical need. The type of drug that has developed most rapidly in the last decade is immunotherapy: vaccines and, especially, passive vaccination with monoclonal antibodies. Antibodies are attractive drugs as they can be made highly specific for their target and often with few side effects. Data from recent clinical AD trials indicate that a treatment… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 39 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 57 references

New composite score demonstrates sensitivity to disease progression and treatment effects. Florence, Italy: Paper presented at the 11th International Conference on Alzheimer’s and Parkinson’s Disease

V Logovinsky, S Hendrix, C Perdomo, J Wang, A Satlin
2013
View 1 Excerpt

Similar Papers

Loading similar papers…